Redhill Biopharma Ltd. - American Depositary Shares (RDHL) analyst actions
Rating and price-target actions on RDHL in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RDHL overview →
3 measured RDHL analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer | Press release | +1.79% | +1.51% | |
| RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer | Press release | +5.92% | -1.52% | |
| RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians | Press release | +0.00% | -4.16% |
Keep exploring
More RDHL: earnings → · SEC filings → · RDHL overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cara Therapeutics, Inc. (CARA) | 143 | -0.56% | 46% |
| Nutriband Inc. (NTRB) | 143 | 0.00% | 44% |
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.